State of the Data 2025: Irix Prescription Data Report

The OG insurtech tool has quietly grown into a multipurpose risk-assessment powerhouse. How well do you really know it?

Individual insurance carriers haven’t stopped using Irix® Prescription Data since it debuted in 2001; in fact, you’re using it more than ever, and adoption is still climbing. And while you’ve relied on Prescription Data to deliver instant risk insight for more than two decades, we’ve added value to this underwriting mainstay along the way that may pleasantly surprise you.

In this “State of the Data 2025: Irix Prescription Data” report, we take a long-overdue look at the compounding ROI of the original insurtech tool, including:

• The relentlessly expanding data network that has grown to capture risk-loaded, niche transactions from specialty, compounding, and institutional pharmacies, as well as from “cash” or other off-insurance fills
• Why Prescription Data isn’t supplanted by any other data source
• Advances in interpretation gleaned from data synergies with our other products
• Data source redundancies that make for a resilient “data supply chain” to keep your business humming amid breaches, outages, and other disruptions
• Its foundational input for advanced innovations such as the Irix Risk Score predictive model and our unique, claims-driven Irix EHR
• Charts, graphs, case studies, and numbers that reveal benefits you likely haven’t considered

Prescription Data may be table stakes for individual insurance carriers, but its ROI is anything but ordinary. We don’t take it for granted, and neither should you. Get this report to learn why Prescription Data is essential to your plans for innovation, growth, and continuity—and how you can depend on it to move your business forward.